Article citationsMore>>

Went, P., Agostinelli, C., Gallamini, A., Piccaluga, P.P., Ascani, S., Sabattini, E., Bacci, F., Falini, B., Motta, T., Paulli, M., Artusi, T., Piccioli, M., Zinzani, P.L. and Pileri, S.A. (2006) Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score. Journal of Clinical Oncology, 24, 2472-2479.
https://doi.org/10.1200/JCO.2005.03.6327

has been cited by the following article:

• TITLE: Sustained Remission with Mogamulizumab in Peripheral T Cell Lymphoma with Aberrant CD20 Expression: Case Report and Literature Review

  AUTHORS: Kentaro Fukushima, Hiroshi Sata, Masami Imakita, Takahiro Karasuno

  KEYWORDS: Peripheral T Cell Lymphoma, CD20, PTCL-NOS, Aberrant Expression, Mogamulizumab

  JOURNAL NAME: Journal of Cancer Therapy, Vol.9 No.3, March 6, 2018

  ABSTRACT: A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19 or CD20, however, rare cases have been reported in the literature that showed PTCL patients expressing the B cell antigens. It is considered that the prognosis of CD20 positive PTCL is poor, however, standard therapy has not been established. He was treated with eight cycles of CHOP regimen, but the enlargement of a part of lymph nodes still remained. Recently, it is reported that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50% case of PTCL and CCR4 target therapy is effective. Our case was positive for CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently, dramatic response was obtained and its combination of these therapy resulted in complete remission for 24 months. This is the first case of sustained remission by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This strategy may be benefit to obtain the good prognosis.